- Association of Immune-Related Adverse Events and the Efficacy of Anti–PD-(L)1 Monotherapy in Non–Small Cell Lung Cancer: Adjusting for Immortal-Time Bias
-
Yu Y, Chen N, Yu S, Shen W, Zhai W, Li H, Fan Y
- KMID: 2557662
- Cancer Res Treat.
- 2024 Jul;56(3):751-764.
- doi: 10.4143/crt.2023.1118
Purpose The association between immune-related adverse events (irAEs) and survival outcomes in non–small cell lung cancer (NSCLC) patients treated with programmed death-(ligand) 1 [PD-(L)1] inhibitors remains controversial, partly due to... -
- CITED
-
- Close
- SHARE
-
- Close
